Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction?
暂无分享,去创建一个
J. Izopet | C. Solas | G. Peytavin | I. Poizot-Martin | D. Salmon | E. Pambrun | M. Winnock | S. Dominguez | R. Garraffo | F. Bani-Sadr
[1] J. Benito,et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. , 2012, Journal of hepatology.
[2] A. Curran,et al. Abacavir Coadministration Does Not Interfere with the Suppressive Activity of Ribavirin in An HCV Replicon System , 2011, Antiviral therapy.
[3] F. Stanke-Labesque,et al. [Evidence-based therapeutic drug monitoring for ribavirine]. , 2011, Therapie.
[4] A. Neumann,et al. Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients , 2011, Journal of viral hepatitis.
[5] F. Stanke-Labesque,et al. [Evidence-based therapeutic drug monitoring for ribavirine]. , 2011, Therapie.
[6] D. Neau,et al. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 , 2010, BMC infectious diseases.
[7] Ross J. Harris,et al. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] J. Kostman,et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients , 2010, Antiviral therapy.
[9] P. Marquet,et al. Ribavirin therapeutic drug monitoring: why, when and how? , 2009, Fundamental & clinical pharmacology.
[10] M. Vogel,et al. The treatment of chronic hepatitis C virus infection in HIV co-infection , 2009, European Journal of Medical Research.
[11] V. Soriano,et al. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. , 2008, The Journal of antimicrobial chemotherapy.
[12] C. Tural,et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. , 2008, The Journal of antimicrobial chemotherapy.
[13] J. Gatell,et al. Abacavir does not Influence the Rate of Virological Response in HIV–HCV-Coinfected Patients Treated with Pegylated Interferon and Weight-Adjusted Ribavirin , 2008, Antiviral therapy.
[14] V. Soriano,et al. Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir , 2008, Antiviral therapy.
[15] J. Pineda,et al. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. , 2007, The Journal of antimicrobial chemotherapy.
[16] C. Tural,et al. Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection , 2007, AIDS.
[17] F. Carrat,et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? , 2007, Journal of acquired immune deficiency syndromes.
[18] Giorgio Palù,et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.
[19] N. Margot,et al. In Vitro Combination Studies of Tenofovir and Other Nucleoside Analogues with Ribavirin against HIV-1 , 2005, Antiviral therapy.
[20] Henry J. Kaiser,et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.